FS-67 in the Treatment of Pediatric Patients With Ankle Sprain
NCT ID: NCT01037816
Last Updated: 2022-10-06
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
252 participants
INTERVENTIONAL
2009-12-31
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
HKT-500 in Adult Patients With Ankle Sprain
NCT00680784
Efficacy and Safety of Ketoprofen Topical Patch 20% in the Treatment of Pain Associated With Ankle Sprain or Strain
NCT00351104
HKT-500 in the Treatment of Adult Patients With Ankle Sprain
NCT00927641
Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ankle Sprain
NCT02324270
A Multicenter Efficacy Study of a Diclofenac+Menthol Gel in Subjects With Ankle Sprain
NCT02100670
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
FS-67 patch
One FS-67 patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
FS-67 Patch
One FS-67 patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
Placebo Patch
One placebo patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
Placebo Patch
One placebo patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FS-67 Patch
One FS-67 patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
Placebo Patch
One placebo patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
13 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hisamitsu Pharmaceutical Co., Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yoshinobu Higashi
Role: STUDY_DIRECTOR
Hisamitsu Pharmaceutical Co., Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hisamitsu Investigator Site
Birmingham, Alabama, United States
Hisamitsu Investigator Site
Tucson, Arizona, United States
Hisamitsu Investigator Site
Tucson, Arizona, United States
Hisamitsu Investigator Site
Hot Springs, Arkansas, United States
Hisamitsu Investigator Site
Anaheim, California, United States
Hisamitsu Investigator Site
Bell Gardens, California, United States
Hisamitsu Investigator Site
Long Beach, California, United States
Hisamitsu Investigator Site
Los Angeles, California, United States
Hisamitsu Investigator Site
Boynton Beach, Florida, United States
Hisamitsu Investigator Site
Daytona Beach, Florida, United States
Hisamitsu Investigator Site
Doral, Florida, United States
Hisamitsu Investigator Site
Jacksonville, Florida, United States
Hisamitsu Investigator Site
Evansville, Indiana, United States
Hisamitsu Investigator Site
Topeka, Kansas, United States
Hisamitsu Investigator Site
Bellevue, Nebraska, United States
Hisamitsu Investigator Site
Lincoln, Nebraska, United States
Hisamitsu Investigator Site
Las Vegas, Nevada, United States
Hisamitsu Investigator Site
Berlin, New Jersey, United States
Hisamitsu Investigator Site
Charlotte, North Carolina, United States
Hisamitsu Investigator Site
Columbus, Ohio, United States
Hisamitsu Investigator Site
Dayton, Ohio, United States
Hisamitsu Investigator Site
El Paso, Texas, United States
Hisamitsu Investigator Site
Grapevine, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FS-67-HP01-E02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.